Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 2.93% is in line with its 5-year average of 2.77%, near the high end of its 5-year range (-2.30%–4.08%).
1.69% below its 12-month average of 2.98%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 3.05%.
NET PROFIT MARGIN
2.93%
NET PROFIT MARGIN AVG TTM
2.98%
NET PROFIT MARGIN AVG 3Y
3.09%
NET PROFIT MARGIN AVG 5Y
2.77%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.69%
CURRENT VS 3Y AVG
-5.17%
CURRENT VS 5Y AVG
+5.95%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+937.14%
vs the sector median at left
The Pennant Group, Inc.
Market Cap
$1.39B
Net Profit Margin
2.93%
TTM Avg
2.98%
3Y Avg
3.09%
5Y Avg
2.77%
Market Cap
$1.40B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.40B
Net Profit Margin
-2728.04%
TTM Avg
-1093.44%
3Y Avg
-2386.05%
5Y Avg
-1590.70%
Market Cap
$1.37B
Net Profit Margin
-10773.46%
TTM Avg
416506.27%
3Y Avg
203244.58%
5Y Avg
135206.06%
Market Cap
$1.42B
Net Profit Margin
82.37%
TTM Avg
-82.37%
3Y Avg
-592.43%
5Y Avg
-414.63%
Market Cap
$1.42B
Net Profit Margin
-81.79%
TTM Avg
-93.52%
3Y Avg
-130.36%
5Y Avg
-119.92%
Market Cap
$1.34B
Net Profit Margin
324.88%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.44B
Net Profit Margin
-16.75%
TTM Avg
-1.75%
3Y Avg
-3.69%
5Y Avg
-6.61%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| The Pennant Group, Inc. (PNTG) | $1.39B | 2.93% | 2.98% | 3.09% | 2.77% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | 0.00% | 0.00% | 0.00% | 0.00% |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | -2728.04% | -1093.44% | -2386.05% | -1590.70% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | -10773.46% | 416506.27% | 203244.58% | 135206.06% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 82.37% | -82.37% | -592.43% | -414.63% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | -81.79% | -93.52% | -130.36% | -119.92% |
| Omeros Corporation (OMER)vs › | $1.34B | 324.88% | 0.00% | 0.00% | 0.00% |
| Certara, Inc. (CERT)vs › | $1.44B | -16.75% | -1.75% | -3.69% | -6.61% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 6.59% | 2.75% | 2.46% | 3.07% |
Operating Margin
5.8%
Net Profit Margin
2.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 3.05% |
| 2026-03-31 | 2.99% |
| 2025-12-31 | 2.99% |
| 2025-09-30 | 2.66% |
| 2025-06-30 | 3.23% |
| 2025-03-31 | 3.71% |
| 2024-12-31 | 3.05% |
| 2024-09-30 | 3.43% |
| 2024-06-30 | 3.37% |
| 2024-03-31 | 3.13% |
| 2023-12-31 | 2.98% |
| 2023-09-30 | 3.13% |
| 2023-06-30 | 2.11% |
| 2023-03-31 | 1.46% |
| 2022-12-31 | 2.79% |
| 2022-09-30 | 4.08% |
| 2022-06-30 | -2.30% |
| 2022-03-31 | 0.89% |
| 2021-12-31 | -1.92% |
| 2021-09-30 | 1.11% |
| 2021-06-30 | 2.40% |
| 2021-03-31 | 0.90% |
| 2020-12-31 | 3.72% |
| 2020-09-30 | 4.48% |
| 2020-06-30 | 4.68% |
| 2020-03-31 | 3.24% |
| 2019-12-31 | -4.25% |
| 2019-09-30 | 1.72% |
| 2019-06-30 | 4.21% |
| 2019-03-31 | 1.71% |
| 2018-12-31 | 5.00% |
| 2018-09-30 | 5.99% |
| 2018-06-30 | 5.96% |
| 2018-03-31 | 4.97% |
